Diagnosis and therapy of postmenopausal osteoporosis in clinical practice

DOI: https://doi.org/10.29296/25877305-2022-07-10
Issue: 
7
Year: 
2022

Professor V. Strukov(1), MD; D. Elistratov(2); Associate Professor D. Vikhrev(1), Candidate of Medical Sciences; Professor O. Vinogradova(1), MD; Associate Professor L. Musatova(3), Candidate of Medical Sciences; Associate Professor
N. Alekseeva(1), Candidate of Medical Sciences; Associate Professor
L. Radchenko(1), Candidate of Medical Sciences
1-Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
2-Healthy Children Medical Center, Penza
3-Penza State University

Postmenopausal osteoporosis (OP) is the most common form of the disease characterized by a sharp decrease in bone mineral density and by a high fracture risk in the presence of hormonal deficiency associated with the onset of menopause. Specially developed methods for diagnosing OP and therapy that takes into account the etiopathogenesis of the disease can reduce OP-associated disability and mortality rates among menopausal women. The paper presents survey data from 80 women with postmenopausal OP and reveals the potential of morphometric X-ray diagnosis that can assess not only the degree of osteoporotic changes, but also the efficacy of specific drugs.
Keywords: 
therapy
postmenopausal osteoporosis
osteoporosis diagnosis
fractures
Osteomed Forte
osteoporosis therapy
bone mineral density

References: 
  1. Vertkin A.L., Naumov A.V. Osteoporoz. Rukovodstvo dlya prakticheskikh vrachei. M.: EKSMO, 2015 (in Russ.).
  2. Osteoporoz: klinicheskie rekomendatsii. Rossiiskaya assotsiatsiya endokrinologov, Rossiiskaya assotsiatsiya po osteoporozu, Assotsiatsiya revmatologov Rossii i dr. Odobr. Nauchno-prakticheskim sovetom Minzdrava RF. M., 2021 (in Russ.).
  3. Kalinichenko S.Yu., Apetov S.S. Rol’ androgenov u zhenshchin: chto my znaem? Lechashchii vrach. 2010; 8: 78–83 (in Russ.).
  4. Bokov A.E., Mlyavykh S.G., Aleynik A.Ya. et al. The prognostic value of bone density measured in hounsfield units in relation to low energy vertebra fracture prediction. Meditsinskaya vizualizatsiya. 2015; 3: 94–8 (in Russ.).
  5. Krutikova N.Y., Vinogradova A.G., Yudenkova O.A. et al. History of diagnostics implementation for identification of impaired bone density. Vestnik Smolenskoi gosudarstvennoi meditsinskoi akademii. 2018; 4 (17): 146–50 (in Russ.).
  6. Malevich E.E., Vodyanova O.V. Radiation diagnosis methods in the evaluation of osteoporotic vertebral fractures. International reviews: clinical practice and health. 2018; 4 (32): 6–21 (in Russ.).
  7. Rubin M.P. Advantages and disadvantages of dual-energy x-ray osteodensitometry in the diagnosis of osteoporosis. Radiology – practice. 2009; 3: 12–20 (in Russ.).
  8. Burmistrova L.A. Fiziko-khimicheskii analiz i biokhimicheskaya otsenka biologicheskoi aktivnosti trutnevogo rasploda. Dis. ... kand. biol. nauk. Ryazan, 1999; 172 s. (in Russ.).
  9. McClung M. Osteoporosis. Statement emphasizes prevention with estrogen or other drugs. Womens Health. 19, October, 2021.
  10. Strukov V.I., Jones O., Krutyakov E.N. et al. Patent 2511430 Rossiiskaya Federatsiya, MPK A 61 B 6/00, G 01 N 9/36, G 01 N 23/083. Sposob diagnostiki osteoporoza metodom opredeleniya dinamiki zakrytiya polostnykh obrazovanii dlya otsenki effektivnosti primeneniya razlichnykh osteoprotektorov. Zayavitel’ i patentoobladatel’ OOO «Parafarm». № 2012115655/14; zayavl. 19.04.2012; opubl. 10.04.2014. (in Russ.).
  11. Apetov S.S., Kalinchenko S.Yu. The role of sex hormones, androgens and estrogens, in the prevention and treatment of osteoporosis in men and women. Farmateka. 2013; S2: 43–5 (in Russ.).
  12. Strukov V.I., Jones O.V., Krutyakov E.N. et al. Patent 2497533 Rossiiskaya Federatsiya, MPK A 61 K 35/64, A 61 K 33/06, A 61 K 31/592, A 61 K 31/593, A 61P 19/10. Sposob i preparat dlya profilaktiki i lecheniya atipichnogo osteoporoza s normal’noi ili povyshennoi mineralizatsiei kostnoi tkani s nalichiem polostnykh obrazovanii v trabekulyarnykh otdelakh kostei (i emu blizkikh sostoyaniyakh pri izbytochnoi masse i metabolicheskom sindrome). Zayavitel’ i patentoobladatel’ OOO «Parafarm». №2012115654/15; zayavl. 19.04.2012; opubl. 10.11.2013 (in Russ.).
  13. Strukov V.I., Jones O.V., Krutyakov E.N. et al. Patent 2498811 Rossiiskaya Federatsiya, MPK A 61 K 35/64, A 61 K 33/06, A 61 K 31/592, A 61 K 31/593, A 61 P 19/10. Sposob profilaktiki i lecheniya osteoporoza i perelomov kostei i preparat dlya profilaktiki i lecheniya osteoporoza i perelomov kostei. Zayavitel’ i patentoobladatel’ OOO «Parafarm». №2012115653/15; zayavl. 19.04.2012; opubl. 20.11.2013 (in Russ.).
  14. Strukov V.I. Mirovoe otkrytie v bor’be s perelomami i osteoporozom! Poliklinika. 2012; 5-1: 126–7 (in Russ.).
  15. Strukov V., Potapov V., Kislov A. et al. Osteoporosis is a problem of the elderly: to accept or to be treated? Vrach. 2014; 6: 30–2 (in Russ.).
  16. Strukov V.I., Elistratov D.G., Maximova M.N. et al. A way of diagnosing osteoporosis and determining the efficiency of a drug in its treatment. Farmatsiya. 2013; 8: 40–3 (in Russ.).
  17. Strukov V.I., Katyushina Yu.G., Filippova O.V. Osteomed – effektivnyi regulyator mineral’noi plotnosti kostei i zakrytiya polostnykh obrazovanii pri lechenii presenil’nogo i senil’nogo osteoporoza. Poliklinika. 2013; 1 (1): 90–1 (in Russ.).
  18. Strukov V., Kislov A., Elistratov D. et al. Personified approach in the therapy of osteoporosis in elderly patients. Vrach. 2015; 6: 51–3 (in Russ.).
  19. Trifonov V., Elistratov D. Recommendations for the treatment of osteoporosis with the drug «Osteomed Forte»and phytopreparations. Vrach. 2018; 29 (5): 87–8 (in Russ.).
  20. Yarmolovich R., Salaev A. Osteomed Forte used to improve the regenerative capacity of bone tissue in diaphyseal tubular bone fractures. Vrach. 2020; 31 (5): 63–6. (in Russ.). DOI: 10.29296/25877305-2020-05-14